Benoit Trottier

Summary

Country: Canada

Publications

  1. ncbi Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
  2. ncbi Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Canada
    HIV Clin Trials 11:175-85. 2010
  3. ncbi Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    HIV Clin Trials 13:335-42. 2012
  4. ncbi Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
  5. ncbi A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
    Julian Falutz
    Montreal General Hospital Immuno-Deficiency Treatment Centre, McGill University Health Center, , Quebec, Canada
    AIDS 19:1279-87. 2005
  6. ncbi Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Virol 85:5949-60. 2011

Collaborators

Detail Information

Publications6

  1. ncbi Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
    ..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
  2. ncbi Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Canada
    HIV Clin Trials 11:175-85. 2010
    ..This subgroup analysis of the phase 3 DUET trials examined the impact of the background regimen on virologic response to etravirine in treatment-experienced patients...
  3. ncbi Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    HIV Clin Trials 13:335-42. 2012
    ..Conclusions: The new combination of ABC/3TC/DRV/r demonstrates a high rate of antiviral activity with no major toxicity. The drug combination appears to be generally safe and well tolerated...
  4. ncbi Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
    ..A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change...
  5. ncbi A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
    Julian Falutz
    Montreal General Hospital Immuno-Deficiency Treatment Centre, McGill University Health Center, , Quebec, Canada
    AIDS 19:1279-87. 2005
    ..TH9507 may be a beneficial treatment strategy in this population, but longer-term studies with more patients are needed to determine effects on VAT, treatment durability, and safety...
  6. ncbi Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Virol 85:5949-60. 2011
    ..The protective effect of HLA-B*57 on slow progression to AIDS and low VL may be mediated through its interaction with KIR3DL1 alleles to educate NK cells for potent activity upon stimulation...